Form 4: TransMedics Director David Weill Reports Stock Sale and RSU Grant Under 10b5-1 Plan

TransMedics Group, Inc. Director David Weill reported the acquisition of 2,134 restricted stock units and the sale of 732 shares of common stock, both occurring in May 2025.

Summary

• David Weill, a Director of TransMedics Group, Inc. (TMDX), filed a Form 4 to report changes in his beneficial ownership.
• On May 22, 2025, Mr. Weill acquired 2,134 restricted stock units (RSUs) at a price of $0, with each RSU representing a contingent right to receive one share of the Issuer's common stock.
• Following the RSU acquisition, Mr. Weill's direct beneficial ownership of common stock was reported as 12,866 shares.
• On May 23, 2025, Mr. Weill sold 732 shares of TransMedics common stock at a price of $123.88 per share.
• After these reported transactions, Mr. Weill's direct beneficial ownership of common stock stands at 12,134 shares.
• The reported transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction involving both an equity grant (RSUs) and a sale of common stock under a pre-arranged 10b5-1 plan. While the RSU grant is positive for aligning interests, the sale, even if planned, represents a reduction in direct ownership, leading to a neutral to slightly negative sentiment.

Positives

• The acquisition of 2,134 restricted stock units (RSUs) indicates ongoing equity compensation for the director, which helps align his interests with those of the company's shareholders.
• The sale of shares was conducted under a Rule 10b5-1(c) plan, suggesting a pre-arranged, non-discretionary transaction rather than a reaction to recent company performance or a discretionary decision based on inside information.

Negatives

• A director selling shares, even a relatively small amount and under a pre-arranged plan, could be perceived by some investors as a slight reduction in the director's direct equity commitment to the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the sale as a slight negative signal regarding the director's direct equity stake, although this is mitigated by the transaction being part of a pre-arranged 10b5-1 plan. The RSU grant is a standard form of equity compensation.

Key Dates

Recommendation

Keywords

TransMedics Group, TMDX, SEC Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Director, David Weill, Beneficial Ownership, Equity Compensation, 10b5-1 Plan